Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIX NASDAQ:APVO NASDAQ:CBIO NASDAQ:NERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$3.05+1.7%$2.83$2.44▼$5.46$102.27M0.64147,848 shs50,294 shsAPVOAptevo Therapeutics$4.88-8.9%$5.14$3.80▼$258.01$5.75M1.64134,841 shs404,866 shsCBIOCrescent Biopharma$18.04-0.2%$16.27$8.72▼$27.50$496.85M1.21227,280 shs43,416 shsNERVMinerva Neurosciences$6.17-1.2%$6.52$1.30▼$12.46$269.84M-0.08204,422 shs36,805 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences-4.46%-0.33%+17.65%+2.74%+6.76%APVOAptevo Therapeutics+8.74%+8.96%+28.30%-16.54%-96.62%CBIOCrescent Biopharma+0.06%-24.54%-6.80%+86.20%-97.64%NERVMinerva Neurosciences+2.97%-2.95%+18.37%+33.83%+265.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$3.05+1.7%$2.83$2.44▼$5.46$102.27M0.64147,848 shs50,294 shsAPVOAptevo Therapeutics$4.88-8.9%$5.14$3.80▼$258.01$5.75M1.64134,841 shs404,866 shsCBIOCrescent Biopharma$18.04-0.2%$16.27$8.72▼$27.50$496.85M1.21227,280 shs43,416 shsNERVMinerva Neurosciences$6.17-1.2%$6.52$1.30▼$12.46$269.84M-0.08204,422 shs36,805 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences-4.46%-0.33%+17.65%+2.74%+6.76%APVOAptevo Therapeutics+8.74%+8.96%+28.30%-16.54%-96.62%CBIOCrescent Biopharma+0.06%-24.54%-6.80%+86.20%-97.64%NERVMinerva Neurosciences+2.97%-2.95%+18.37%+33.83%+265.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIXAnixa Biosciences 2.25Hold$8.50178.69% UpsideAPVOAptevo Therapeutics 2.33HoldN/AN/ACBIOCrescent Biopharma 3.11Buy$28.0055.21% UpsideNERVMinerva Neurosciences 2.00Hold$10.5070.07% UpsideCurrent Analyst Ratings BreakdownLatest NERV, APVO, CBIO, and ANIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2026CBIOCrescent Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/24/2026APVOAptevo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/15/2026NERVMinerva Neurosciences Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$14.004/8/2026ANIXAnixa Biosciences D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.003/31/2026ANIXAnixa Biosciences D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.003/27/2026NERVMinerva Neurosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/12/2026NERVMinerva Neurosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$4.00 ➝ $7.003/2/2026CBIOCrescent Biopharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$25.00 ➝ $22.002/26/2026CBIOCrescent Biopharma Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$29.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIXAnixa Biosciences$210K486.98N/AN/A$0.42 per share7.26APVOAptevo TherapeuticsN/AN/AN/AN/A$17.42 per shareN/ACBIOCrescent Biopharma$10.84M45.87N/AN/A$6.53 per share2.76NERVMinerva NeurosciencesN/AN/AN/AN/A($3.25) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIXAnixa Biosciences-$10.93M-$0.33N/AN/AN/AN/A-70.95%-62.53%5/27/2026 (Estimated)APVOAptevo Therapeutics-$25.97M-$1,770.33N/AN/AN/AN/A-260.82%-132.90%5/21/2026 (Estimated)CBIOCrescent Biopharma-$153.94M-$10.91N/AN/AN/AN/A-103.44%-88.19%N/ANERVMinerva Neurosciences-$293.42M-$26.80N/AN/AN/AN/AN/A-35.62%5/12/2026 (Estimated)Latest NERV, APVO, CBIO, and ANIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/27/2026Q2 2026ANIXAnixa Biosciences-$0.09N/AN/AN/AN/AN/A5/21/2026N/AAPVOAptevo Therapeutics-$5.60N/AN/AN/AN/AN/A5/13/2026N/ACBIOCrescent Biopharma-$0.85N/AN/AN/A$0.36 millionN/A5/12/2026Q1 2026NERVMinerva Neurosciences-$0.13-$0.17-$0.04-$2.86N/AN/A4/29/2026Q1 2026CBIOCrescent Biopharma-$0.85-$0.70+$0.15-$0.70$0.36 million$1.04 million3/27/2026Q4 2025APVOAptevo Therapeutics-$8.10$118.23+$126.33$118.23N/AN/A3/9/2026Q1 2026ANIXAnixa Biosciences-$0.09-$0.08+$0.01-$0.08N/AN/A2/26/2026Q4 2025CBIOCrescent Biopharma-$2.22-$4.01-$1.79-$4.01N/A$10.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANIXAnixa BiosciencesN/AN/AN/AN/AN/AAPVOAptevo TherapeuticsN/AN/AN/AN/AN/ACBIOCrescent BiopharmaN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIXAnixa BiosciencesN/A12.1812.18APVOAptevo TherapeuticsN/A3.823.82CBIOCrescent BiopharmaN/A13.7813.78NERVMinerva NeurosciencesN/A36.2936.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIXAnixa Biosciences29.13%APVOAptevo Therapeutics8.06%CBIOCrescent Biopharma75.19%NERVMinerva Neurosciences34.56%Insider OwnershipCompanyInsider OwnershipANIXAnixa Biosciences26.40%APVOAptevo Therapeutics0.08%CBIOCrescent Biopharma8.70%NERVMinerva Neurosciences10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIXAnixa Biosciences533.53 million24.68 millionOptionableAPVOAptevo Therapeutics501.18 million1.18 millionNot OptionableCBIOCrescent Biopharma5027.56 million25.16 millionNo DataNERVMinerva Neurosciences943.84 million39.28 millionNot OptionableNERV, APVO, CBIO, and ANIX HeadlinesRecent News About These CompaniesMinerva Neurosciences, Inc: Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business UpdatesMay 5 at 10:27 PM | finanznachrichten.deMinerva Neurosciences (NASDAQ:NERV) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPSMay 5 at 9:24 AM | marketbeat.comMinerva Neurosciences Provides First Quarter 2026 Financial Results and Business UpdatesMay 5 at 8:00 AM | globenewswire.comMinerva Neurosciences, Inc (NASDAQ:NERV) Short Interest UpdateMay 1, 2026 | marketbeat.comMinerva Neurosciences (NERV) price target increased by 31.03% to 9.69April 28, 2026 | msn.comCitizens Initiates Coverage of Minerva Neurosciences (NERV) with Market Outperform RecommendationApril 16, 2026 | msn.comMinerva launched with New Outperform at Citizens on schizophrenia candidateApril 15, 2026 | seekingalpha.comMinerva Neurosciences (NASDAQ:NERV) Now Covered by Citizens JmpApril 15, 2026 | marketbeat.comMinerva Neurosciences, Inc (NASDAQ:NERV) Sees Significant Growth in Short InterestApril 13, 2026 | marketbeat.comMinerva Neurosciences (NASDAQ:NERV) Shares Cross Below Fifty Day Moving Average - Should You Sell?April 8, 2026 | marketbeat.comMinerva Neurosciences Sets 2026 Annual Shareholder Meeting TimelineApril 6, 2026 | tipranks.comMinerva Announces Leadership TransitionApril 2, 2026 | globenewswire.comMinerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of SchizophreniaMarch 31, 2026 | globenewswire.comMinerva Neurosciences: Plodding Ahead After Another Roluperidone Delay In Negative Symptoms Of SchizophreniaMarch 31, 2026 | seekingalpha.comMinerva Neurosciences (NERV) price target increased by 61.11% to 7.40March 27, 2026 | msn.comMinerva Neurosciences, Inc: Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026March 25, 2026 | finanznachrichten.deMinerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026March 25, 2026 | globenewswire.comMinerva Neurosciences to Participate in The Stifel 2026 Virtual CNS ForumMarch 12, 2026 | globenewswire.comMinerva Neurosciences, Inc: Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business UpdatesMarch 11, 2026 | finanznachrichten.deMinerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business UpdatesMarch 11, 2026 | globenewswire.comMinerva Neurosciences to Participate in The Citizens Life Sciences ConferenceMarch 4, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNERV, APVO, CBIO, and ANIX Company DescriptionsAnixa Biosciences NASDAQ:ANIX$3.05 +0.05 (+1.67%) As of 12:14 PM EasternAnixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Aptevo Therapeutics NASDAQ:APVO$4.88 -0.48 (-8.88%) As of 12:32 PM Eastern This is a fair market value price provided by Massive. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Crescent Biopharma NASDAQ:CBIO$18.04 -0.04 (-0.22%) As of 12:32 PM Eastern This is a fair market value price provided by Massive. Learn more.Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.Minerva Neurosciences NASDAQ:NERV$6.17 -0.08 (-1.22%) As of 12:31 PM Eastern This is a fair market value price provided by Massive. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
